Pfizer India Seeks Local Authorization for its COVID-19 mRNA Vaccine

Pfizer India is reported by the Times of India on December 6, 2020, to become the first pharmaceutical firm to approach the Drugs Controller General of India seeking authorization for its experimental COVID-19 mRNA vaccine candidate, BNT162b2, in India.

Previously, Pfizer announced vaccine distribution agreements with the countries of the United Kingdom and the Kingdom of Bahrain.

The COVID-19 mRNA vaccine is a nucleoside-modified RNA, formulated in lipid nanoparticles, and encodes an optimized SARS-CoV-2 full-length spike protein antigen.